Filtered By:
Condition: Diabetes
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 723 results found since Jan 2013.
Lipid-Modifying Therapies and Stroke Prevention
Curr Neurol Neurosci Rep. 2022 May 13. doi: 10.1007/s11910-022-01197-4. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: We reviewed lipid-modifying therapies and the risk of stroke and other cerebrovascular outcomes, with a focus on newer therapies.RECENT FINDINGS: Statins and ezetimibe reduce ischemic stroke risk without increasing hemorrhagic stroke risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors similarly reduce ischemic stroke risk in statin-treated patients with atherosclerosis without increasing hemorrhagic stroke, even with very low achieved low-density lipoprotein cholesterol levels. Icosape...
Source: Atherosclerosis - May 13, 2022 Category: Cardiology Authors: Daniel G Hackam Robert A Hegele Source Type: research
Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease
Fertil Steril. 2022 May;117(5):924-935. doi: 10.1016/j.fertnstert.2022.03.009.ABSTRACTPolycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and is hallmarked by hyperandrogenism, oligo-ovulation, and polycystic ovarian morphology. Polycystic ovary syndrome, particularly the hyperandrogenism phenotype, is associated with several cardiometabolic abnormalities, including obesity, dyslipidemia, elevated blood pressure, and prediabetes or type 2 diabetes. Many, but not all, studies have suggested that PCOS is associated with increased risk of cardiovascular disease (CVD), includi...
Source: Atherosclerosis - May 5, 2022 Category: Cardiology Authors: Carolyn Guan Salman Zahid Anum S Minhas Pamela Ouyang Arthur Vaught Valerie L Baker Erin D Michos Source Type: research
Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome
Exp Ther Med. 2022 Jun;23(6):378. doi: 10.3892/etm.2022.11305. Epub 2022 Apr 8.ABSTRACTThe link between inflammation and acute coronary syndrome (ACS) remains to be sufficiently elucidated. It has been previously suggested that there is an inflammatory process associated with ACS. Pentoxifylline, a methylxanthine derivate, is known to delay the progression of atherosclerosis and reduce the risk of vascular events, especially by modulating the systemic inflammatory response. The present study is a single-blind, randomized, prospective study of pentoxifylline 400 mg three times a day (TID) added to standard therapy vs. stand...
Source: Experimental and Therapeutic Medicine - May 2, 2022 Category: General Medicine Authors: Daniel Miron Brie Cristian Mornos Diduta Alina Brie Constantin Tudor Luca Lucian Petrescu Madalina Boruga Source Type: research
